Johnson & Johnson Emerges as Defensive Leader Amid AI Sector Volatility
Johnson & Johnson (JNJ) is being highlighted as a primary beneficiary of a market rotation from volatile artificial intelligence stocks into defensive sectors like healthcare and consumer staples. While tech stocks have declined over 9% recently due to political uncertainty and leadership concerns at Nvidia, healthcare and consumer staples have seen gains of 7% and 6%, respectively. J&J's recent performance is bolstered by its acquisition of Ollin Biosciences for up to $3.33 billion to expand its eye disease treatment portfolio. Despite some recent weakness in its MedTech segment, the company maintains strong fundamentals driven by a robust pharmaceutical pipeline, including treatments for blood cancer and plaque psoriasis. The company also plans to spin off its orthopedics business by 2027 to drive growth.

Topics: Acquisition Healthcare Pharmaceuticals Stock Performance